Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in connection with a capital procurement of MSEK 220
Mandate

Vinge advises Smart Eye in connection with a capital procurement of MSEK 220

November 01, 2021 Capital Markets and Public M&A

Vinge has advised Smart Eye Aktiebolag in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 220 to Smart Eye.

The subscription price of SEK 183 SEK, which corresponded to the closing price on Nasdaq First North Growth Market, was determined through an accelerated book-building procedure arranged by Carnegie. The proceeds will primarily be used to finance the acquisition of iMotions A/S, which was published on the same day.

Vinge’s team primarily consisted of Anders Strid, Edin Agic, Oscar Lunde and Adrian Filipovic.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026